Current options in the prevention of thromboembolic disease.
about
Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal periodSafety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirinNovel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.The discovery and development of rivaroxaban.Coumarin-based drugs: a patent review (2008 -- present).Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery.Pharmacogenetic aspects of coumarinic oral anticoagulant therapies.Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study.
P2860
Q24200433-4EAE571F-CCFD-46E3-9E0A-2615F932C879Q28200198-F587E232-3B27-4962-B671-AE293375E350Q34549913-4A5E1AEB-383E-4E55-A485-50756FBB3832Q34564159-9D09D15A-2978-43D2-B50C-A4C625D04A1DQ37321425-E1A01040-DDC0-4FBB-BE75-EC93F44CE876Q37857332-718611C2-8408-47E3-8E8C-B3FB78AC3527Q37999915-F4D1B2FA-38BD-45B8-8DFF-52856EBE9FF0Q38201452-A20EA51D-F6CF-457C-9963-35512D2C32D5Q38266460-749CDF0E-D992-4AF7-B7A8-FCB0DC64108AQ42123361-25C1E967-FE2D-4074-9DB5-2765EEF75FC5Q51028422-91B241B3-AFE5-419D-9686-0B9E2C041440
P2860
Current options in the prevention of thromboembolic disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Current options in the prevention of thromboembolic disease.
@ast
Current options in the prevention of thromboembolic disease.
@en
type
label
Current options in the prevention of thromboembolic disease.
@ast
Current options in the prevention of thromboembolic disease.
@en
prefLabel
Current options in the prevention of thromboembolic disease.
@ast
Current options in the prevention of thromboembolic disease.
@en
P1433
P1476
Current options in the prevention of thromboembolic disease.
@en
P2093
David Bergqvist
Jack Ansell
P356
10.2165/00003495-200464001-00002
P478
64 Suppl 1
P577
2004-01-01T00:00:00Z
P6179
1042094257